Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 16, 2019 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 7,000 | $11.92 | 68,774 | |
| Jul 16, 2019 | Director | Form 4 | Open market or private sale of non-derivative or derivative security | 13,650 | $21.45 | 55,124 | |
| Jul 16, 2019 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 6,650 | -- | -- | |
| Jul 16, 2019 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 7,000 | -- | -- | |
| Jul 17, 2019 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,057 | -- | 21,340 | |
| Jul 17, 2019 | SVP and GM of Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,226 | -- | 16,769 | |
| Jul 17, 2019 | SVP and GM of Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,790 | -- | 10,790 | |
| Jul 17, 2019 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,098 | -- | 19,748 | |
| Jul 17, 2019 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,361 | -- | 10,361 | |
| Jul 17, 2019 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,104 | -- | 146,580 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.